
Opinion|Videos|February 7, 2025
Opportunities for Easing BTK Inhibitor Switches
Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of multiple challenges including optimal timing of the switch, potential washout periods, dose adjustments, patient education about expected adverse effects, and close monitoring during the transition period to maintain treatment efficacy while minimizing complications.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What challenges do you face when switching between BTK inhibitors, and what strategies can help mitigate these challenges?
- How can oncologists better educate patients about the potential for switching BTK inhibitors to manage toxicities without compromising treatment outcomes?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation
4
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
5
















































